Quisinostat

An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
02420132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Histone deacetylases (HDACs) are known to be key enzymes in cancer development and progression through their modulation of… (More)
Is this relevant?
2017
2017
Abnormal epigenetic modifications are considered a main contributing factor to low cloning efficiency. In the present study, we… (More)
Is this relevant?
2017
2017
Histone deacetylase inhibitor (HDACi) has been a major target of anticancer agents. Quisinostat (JNJ‑26481585), a novel second… (More)
Is this relevant?
2017
2017
Conventional cytotoxic therapies for synovial sarcoma provide limited benefit, and no drugs specifically targeting its driving… (More)
Is this relevant?
2016
2016
The maximum tolerated dose (MTD) of quisinostat + bortezomib + dexamethasone in patients with relapsed multiple myeloma was… (More)
Is this relevant?
2016
2016
The reversibility of non-genotoxic phenotypic changes has been explored in order to develop novel preventive and therapeutic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
BACKGROUND Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor. OBJECTIVES To… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
BACKGROUND Quisinostat (JNJ-26481585) is a second-generation pyrimidyl-hydroxamic acid histone deacetylase (HDAC) inhibitor with… (More)
Is this relevant?
2014
2014
PURPOSE Uveal melanoma (UM) is fatal in up to 50% of patients because of liver metastases that are refractory to therapies… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?